> ## Content Index
> Fetch the complete content index at: https://bioweek.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# What blocking Activin A means for FOP — Regeneron’s Pasatru and a disease that turns muscle into bone
- URL: https://bioweek.com/regeneron-pasatru-fop/
- Published: 2026-08-19T14:00:00.000Z
- Updated: 2026-08-27T18:02:27.000Z
- Description: FDA approved garetosmab on 19 August as the first FOP drug shown, in a placebo-controlled trial, to cut both new heterotopic-ossification lesions (by ≥90%) and clinician-assessed flare-ups.
- Author: BioWeek
- Tags: Science

Fibrodysplasia ossificans progressiva is the textbook gain-of-function receptor disease. A missense mutation in *ACVR1* (ALK2) converts a bone morphogenetic protein receptor that should ignore Activin A into one that treats the ligand as an agonist. Heterotopic ossification follows: muscle, tendon and ligament progressively replaced by bone, flare by flare, until the skeleton that was not supposed to be there locks the one that was. On 19 August 2026 the FDA approved [Pasatru (garetosmab-grts)](https://investor.regeneron.com/news-releases/news-release-details/pasatrutm-garetosmab-grts-first-and-only-fda-approved-treatment?ref=bioweek.com) to reduce formation of new HO lesions and clinician-assessed flare-ups in adults with FOP. Regeneron presents the antibody as the product of a mechanistic claim the company has been making for a decade: its scientists identified Activin A as the ligand that drives HO in FOP, then built a VelocImmune fully human monoclonal antibody that binds and neutralizes it.

That is a ligand strategy, not a receptor strategy. Palovarotene (Sohonos), the first U.S. FOP drug, acts downstream of the receptor. Garetosmab tries to take away the signal that the mutant receptor should never have seen. The [International Fibrodysplasia Ossificans Progressiva Association](https://www.ifopa.org/us-fda-approves-regeneron-pharmaceuticals-garetosmab-treatment-fop?ref=bioweek.com) called Pasatru the second U.S. FOP treatment and the first shown to affect both bone growth and flare-ups. It is approved only for adults 18 and older. It does not reverse existing HO. It is not a cure.

## What OPTIMA measured

FOP is tiny, so the trial is tiny. OPTIMA enrolled 63 adults with any FOP-causing *ACVR1* variant, disease activity or HO progression, and a cumulative analogue joint involvement scale (CAJIS) score of 19 or less at screening. They were randomized to garetosmab 10 mg/kg (n=23), 3 mg/kg (n=19), or placebo (n=21), given intravenously every four weeks for 56 weeks. The recommended starting dose on the label is 10 mg/kg over 60 minutes every four weeks, with a decrease to 3 mg/kg if not tolerated; home infusion is permitted where appropriate.

The primary endpoint was the total number of new HO lesions on CT at 56 weeks. Placebo accrued 19 lesions. The 10 mg/kg arm accrued 2 (a 90 percent reduction). The 3 mg/kg arm accrued 1 (a 94 percent reduction). On new bone, both doses worked. On the key secondary endpoint — clinician-assessed flare-ups — they did not. The 10 mg/kg arm had 9 flares, an 88 percent reduction versus 66 on placebo. The 3 mg/kg arm had 53, a 15 percent reduction. Flattening those two doses into a single “flare effect” would misread the label. The dose the FDA starts patients on is the dose that moved flares in the clinic. The dose reserved for intolerance barely moved them.

Patient-reported flare-ups did not separate from placebo at all. Regeneron states that changes in the proportion of patients with patient-reported flares through week 56 were not significantly different between placebo and either Pasatru group. Clinician-assessed events and patient diaries are not the same instrument, and only one of them won. That is a real limitation, not a footnote.

## The 2020 signal, and what OPTIMA did not erase

Garetosmab’s path to a 2026 label ran through a death signal that Regeneron’s 19 August release does not narrate. In the phase 2 LUMINA-1 study, published in [*Nature Medicine*](https://www.nature.com/articles/s41591-023-02561-8?ref=bioweek.com) in 2023, five of 44 patients (11.4 percent) died during the open-label periods. Investigators reported the deaths as unrelated; the paper found no clear pattern linking them to treatment or to Activin A blockade, “although a causal relation cannot be excluded.” Five deaths is a high number for a 44-person study, even in a disease whose natural history includes falls, cardiorespiratory failure and early mortality. [Fierce Pharma](https://www.fiercepharma.com/pharma/regeneron-approval-fop?ref=bioweek.com), covering the approval, reported that the 2020 deaths stalled a planned 2021 filing, that there was no clear link to garetosmab as the cause, and that OPTIMA later recorded no deaths or serious bleeding events. Regeneron’s own 19 August statement is narrower: among all 63 OPTIMA participants at 56 weeks, serious treatment-emergent adverse events occurred in 2 patients on 10 mg/kg, 1 on 3 mg/kg, and 2 on placebo.

The common adverse reactions on the label, occurring in at least 10 percent of adults on either dose, are a recognizable cluster: abscess, acne, increased hair growth, madarosis, oral ulcers, epistaxis, folliculitis, paronychia, and rash. Important safety information flags embryo-fetal toxicity — Pasatru is contraindicated in pregnancy — plus skin and soft-tissue infections that may require hospitalization, and nosebleeds that can be severe. LUMINA-1 had already shown epistaxis, madarosis and skin infections imbalanced versus placebo. OPTIMA did not make those effects disappear. It put them next to a placebo SAE rate that looked similar, in a disease where the alternative to treatment is new bone.

## What the label does not do

Regeneron’s epidemiology is stark and should be read as the company’s: about 900 people diagnosed worldwide, most wheelchair-bound by age 30, median survival 56\. Fierce Pharma puts the U.S. adult opportunity at roughly 220 patients. Those are not claims-database counts. A Phase 3 trial in adolescents and children, OPTIMA 2, is planned to begin later this year; IFOPA notes it is listed on ClinicalTrials.gov but not yet recruiting. A regulatory submission is under review at the EMA. Additional filings, including Japan, are planned. None of that is pediatric approval, and none of it is EU approval.

The mechanistic argument is the one that will travel. If mutant ACVR1 is an Activin A receptor in FOP and a BMP receptor in everyone else, then neutralizing the ligand should stop new HO without needing to occupy ALK2 in every tissue that still needs BMP signaling. OPTIMA’s CT counts are consistent with that prediction for *new* lesions. They say nothing about the ribbons of heterotopic bone already bridging joints. LUMINA-1 had already taught that lesson: existing lesions did not robustly regress, which is why the Phase 2 hypothesis was rewritten around prevention of new HO, and why the Phase 3 primary endpoint was written the same way. Pasatru is a brake on the next lesion. It is not a chisel for the last one.

That distinction will govern use. Starting at 10 mg/kg is not a commercial preference; it is the only dose that moved clinician-assessed flares. Dropping to 3 mg/kg for tolerability keeps most of the CT effect and almost none of the flare effect. Patient-reported flares remain unmoved at either dose. The 2020 deaths remain in the literature, unlinked and unexcluded. A placebo-controlled 90 percent reduction in new lesions is a genuine change in the standard. It is also exactly as large, and as limited, as the endpoint the label was written on.